Company

Telix Pharmaceuticals

Melbourne, VIC

Disclosed deals

Every published round Telix Pharmaceuticals took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.

Company	Stage	Announced	Amount	Role	Alongside	Sources
No published deals recorded yet.

Portfolio

Companies Telix Pharmaceuticals has backed in a published round, and companies whose existing shares it bought off another holder.

Company	What it does	First invested	Rounds	Led
No portfolio companies recorded yet.

Funds

Fund closes reported for Telix Pharmaceuticals, as distinct from the investments it has made.

Fund	Announced	Committed	Target	Close	Sources
No fund closes recorded for Telix Pharmaceuticals yet.

Portfolio companies acquired

Companies Telix Pharmaceuticals has backed that another company then bought. An exit for the holding, not a deal Telix Pharmaceuticals did.

Company	Bought by	Kind	Announced	Price
No portfolio company of Telix Pharmaceuticals is recorded as having been acquired.

What Telix Pharmaceuticals bought

Companies Telix Pharmaceuticals acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.

Company	Kind	Announced	Price	Sources
ITM Isotope Technologies Munich	Merger	21 Sep 2026	≤$3.3b	Biotech Dispatch, Business News Australia

Name	Role	Sources
Dr Christian Behrenbruch	CEO	Biotech Dispatch, Business News Australia, Forbes Australia

Coverage

Stories naming Telix Pharmaceuticals. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

15 deals

🇦🇺 This Week in Australian Startups #179, 26th September 2026

Weekly roundup recording a dozen raises and acquisitions, Firmus's scheduled float, a new $50m venture fund, a founder share sale, grant winners, an accelerator intake, and an AI agent's government breach.

This Week in Australian Startups Sat 26 Sep 2026 Amber Electric Auric CodeBreakers Fever Heidi Health HEO Hubblenetwork Kinoxis Therapeutics Medcast OpenDebt Remagine Labs RentBetter Significant Capital Ventures TasTest Zeligate Advanced Navigation Afterpay Airtasker AirTrunk Airwallex Anthropic AUSTRAC Australian Government Australian Signals Directorate Catch CDC Centre Droneshield Elixinol Wellness Ellerston Capital Employment Hero Firmus Technologies Genetic Signatures Innovaero Investment NSW Kongsberg Luxury Escapes Medicare Microba Life Sciences Morgan Stanley National Transport Solutions Nearmap News Corp NSW Government Ofload OpenAI ParaScript Ramp South Australian Government Spark Capital Stakk Limited Telix Pharmaceuticals Telstra The U Group The University of Sydney Thoma Bravo University of Canberra University of Newcastle UNSW Sydney Victorian Government Vitable 1GT AirTree Ventures Angel Investors Antler Australia Athletic Ventures Avicella Capital Baillie Gifford Beaten Zone Venture Partners Best Practice Blackbird Ventures Carthona Capital CSIRO DCode Capital Deepwater Dumm Capital E.ON EQT ETF Partners EVP General Catalyst Headline Innovation Victoria Main Sequence Ventures Medical Research Future Fund Monash University NRF Corporation Paspalis Phoenix Court Point72 Salus Ventures Scalare Partners Stoic Venture Capital Ten13 Uniseed UniSuper Greg Boorer Pat Cummins Sam Kerr Albanese Anoulack Chanthivong Gabby Leibovich Hezi Leibovich Jack Zhang Jonathan Lui

Also DealStreetAsia·Dealroom·This Week in Australian Startups·AFR Technology·AFR Technology·Startup Daily·AFR Technology·AFR Technology·ABC News Technology·iTnews

Exit / M&A

Telix Pharmaceuticals strikes $3.3b merger with German radioisotope giant ITM

Melbourne's Telix Pharmaceuticals will merge with German radioisotope maker ITM in a deal worth as much as $3.3 billion, keeping about 76 per cent ownership with existing Telix shareholders once completed.

Business News Australia Mon 21 Sep 2026 ITM Isotope Technologies Munich Telix Pharmaceuticals Dr Andrew Cavey Dr Christian Behrenbruch

Also Biotech Dispatch

Exit / M&A

Telix bets $1.7B on ITM to build radiopharma powerhouse

Australian-listed Telix is buying German radioisotope supplier ITM in a $1.65 billion deal with contingent milestone payments, creating an end-to-end radiopharmaceutical business.

Dealroom Mon 21 Sep 2026 ITM Isotope Technologies Munich Telix Pharmaceuticals

News

FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug

Telix Pharmaceuticals has gained US regulatory clearance for its glioma imaging agent Pixclara, a world first, and is now studying the compound in late-stage trials for brain metastases.

Biotech Dispatch Mon 14 Sep 2026 Telix Pharmaceuticals United States Food and Drug Administration (FDA)

Series D+ ~$452m

Brisbane biotech AdvanCell just raised a record $450 million

Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.

Forbes Australia Thu 16 Jul 2026 AdvanCell AstraZeneca Bristol-Myers Squibb Eli Lilly and Company Novartis POINT Biopharma Telix Pharmaceuticals Ally Bridge Group Alpha Wave Bain Capital Life Sciences Brandon Capital Fidelity Qatar Investment Authority (QIA)Sanofi Ventures T. Rowe Price Andrew Adamovich Philina Lee

Exit / M&A

Guided nuclear missile for cancer: Telix prepares for Nasdaq IPO

Telix, an ASX-listed radiopharmaceutical maker headquartered in Melbourne, is preparing a dual US listing; the piece also covers revenue growth, cancer trial results and recalls its 2017 float.

Forbes Australia Thu 6 Jun 2024 CSL Institut de Cancérologie de l'Ouest (ICO)Jefferies Morgan Stanley Telix Pharmaceuticals Dr Caroline Rousseau Dr Christian Behrenbruch

3 deals

Manufacturing news briefs – stories you might have missed

Roundup of Australian manufacturing news: Matrak closes a Series A, Queensland Pacific Metals receives an R&D tax refund, ARENA funds a household energy trial, Ampcontrol appoints a transformation chief, plus policy and launch briefs.

Also @AuManufacturing

News

Starpharma, UQ target new radiopharmaceuticals

Starpharma, two universities, Telix, Clarity and CSIRO launch an ARC-backed radiopharmaceutical research hub with a government grant and industry funding.

@AuManufacturing Thu 27 Jul 2023 Australian Research Council Clarity Pharmaceutical CSIRO Starpharma Telix Pharmaceuticals The University of Sydney University of Queensland Dr Jackie Fairley Kris Thurecht

Something wrong? Tell us

Telix Pharmaceuticals

Disclosed deals

Portfolio

Funds

Portfolio companies acquired

What Telix Pharmaceuticals bought

People

Coverage